There are places where ideas remain suspended—held carefully within glass, within theory, within the early language of possibility. And then there are places where those same ideas begin to stretch, to test their weight against the world beyond the laboratory.
In Copenhagen, that threshold has become increasingly visible.
Within the Innovation District Copenhagen, where research buildings sit close to industry and conversation moves easily between disciplines, a new initiative has been set into motion—one that focuses not on invention alone, but on what comes after. The delicate, often uncertain passage from discovery to scale.
At the center of this effort is the BioInnovation Institute, which has introduced a scale-up program designed to support bio-based startups as they move toward real-world application. Known as “Upscalator,” the initiative gathers funding, infrastructure, and expertise into a single framework, aiming to reduce the distance between promising science and tangible impact.
The challenge it addresses is not unfamiliar. Across Europe, laboratories continue to produce breakthroughs in biosolutions—technologies rooted in biology that can reshape agriculture, food systems, and industrial processes. Yet many of these advances encounter friction at the same point: the transition from controlled environments to industrial reality.
It is here, in this narrow space between proof and production, that progress often slows.
The Upscalator program seeks to widen that passage. Backed by a €25 million grant from the Novo Nordisk Foundation, it offers startups access to pilot facilities, advisory networks, and financial support tailored specifically to the scaling phase. The structure reflects a recognition that innovation is not only about discovery, but about continuity—the ability to carry an idea forward without losing its form.
Within its design are several interconnected elements: a process development lab, a network of industrial service providers, targeted funding mechanisms, and a shared community of companies moving along similar paths. Each component speaks to a different barrier that startups have historically faced, from the cost of manufacturing expertise to the absence of coordinated support.
There is also a broader context unfolding around it.
Biosolutions, once a niche segment of biotechnology, are increasingly positioned as central to the green transition. Projections suggest that the global bioeconomy could approach €778 billion in value by 2035, with millions of jobs tied to its expansion. Denmark, already home to established companies in food, fermentation, and industrial biotech, has quietly assembled the conditions for growth—yet until now, the scaling stage has remained a point of hesitation for many emerging firms.
The initiative does not stand alone. It is part of a longer arc in which Copenhagen is shaping itself as a convergence point for science-driven industries. Investments into institutions like the BioInnovation Institute, including long-term funding frameworks extending into the next decade, suggest a deliberate effort to build not just startups, but an ecosystem capable of sustaining them.
And so, within the district, something begins to shift.
Not dramatically, but steadily.
Startups that once existed in isolation—focused on single breakthroughs, single molecules, single processes—are now drawn into a wider network. Here, scaling is no longer an individual challenge, but a shared undertaking, supported by infrastructure that mirrors the complexity of the problems these companies seek to address.
There is a quiet symmetry in this. Biological systems themselves are networks—interdependent, adaptive, resilient. Perhaps it is fitting that the effort to bring them into industry follows a similar pattern.
The work ahead remains measured. Scaling biology is not a matter of speed alone; it requires precision, patience, and the careful alignment of science, capital, and regulation. But in Copenhagen, the pathway appears less fragmented than before.
And for ideas that have waited long enough within glass and theory, that may be enough to begin moving.
The BioInnovation Institute has launched the “Upscalator” program in Copenhagen to support bio-based startups in scaling their technologies to market. Backed by the Novo Nordisk Foundation, the initiative provides funding, facilities, and advisory support to address key bottlenecks in commercialization and accelerate the role of biosolutions in the green transition.
AI Image Disclaimer
Illustrations are AI-generated and intended for conceptual visualization only.
Sources
Innovation District Copenhagen BioInnovation Institute Novo Nordisk Foundation BioXconomy Pulse 2.0